Advertisement

ADVERTISEMENT

Multiple Myeloma

Dr Laubach
Videos
Dr Laubach Reviews Phase 2 GRIFFIN Study Results in Newly Diagnosed MM
01/10/2022
Jacob Laubach, MD, MPP, Dana-Farber Cancer Institute, discusses new results from the Phase 2 GRIFFIN study of daratumumab as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the ASH 2021 Annual Meeting.
Jacob Laubach, MD, MPP, Dana-Farber Cancer Institute, discusses new results from the Phase 2 GRIFFIN study of daratumumab as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the ASH 2021 Annual Meeting.
Jacob Laubach, MD, MPP,...
01/10/2022
Oncology
Dr Wildgust
Podcasts
Dr Wildgust Reviews CASSIOPEIA Phase 3 Results in First-Line MM
12/15/2021
Mark Wildgust, PhD, highlights results from the Phase 3 CASSIOPEIA study of daratumumab as maintenance therapy in first-line MM treatment after stem cell transplant, presented at the 2021 Annual ASH Meeting.
Mark Wildgust, PhD, highlights results from the Phase 3 CASSIOPEIA study of daratumumab as maintenance therapy in first-line MM treatment after stem cell transplant, presented at the 2021 Annual ASH Meeting.
Mark Wildgust, PhD, highlights...
12/15/2021
Oncology
Dr Wildgust
Podcasts
Dr Wildgust Discusses Racial Disparities in Treatment Patterns, Outcomes in MM
12/14/2021
Mark Wildgust, PhD, reviews real-world evidence examining potential healthcare disparities- highlighting patient characteristics, treatment patterns and outcomes for Black and White patients with multiple myeloma who initiated treatment with...
Mark Wildgust, PhD, reviews real-world evidence examining potential healthcare disparities- highlighting patient characteristics, treatment patterns and outcomes for Black and White patients with multiple myeloma who initiated treatment with...
Mark Wildgust, PhD, reviews...
12/14/2021
Oncology
Dr Fonseca
Videos
Dr Fonseca Highlights Phase 2 GRIFFIN Study Results for Newly Diagnosed MM
12/13/2021
Rafael Fonseca, MD, Mayo Clinic, discusses new results from the Phase 2 GRIFFIN study of daratumumab, as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the 2021 ASH Annual Meeting.
Rafael Fonseca, MD, Mayo Clinic, discusses new results from the Phase 2 GRIFFIN study of daratumumab, as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the 2021 ASH Annual Meeting.
Rafael Fonseca, MD, Mayo Clinic,...
12/13/2021
Oncology
pgr
Conference Coverage
Safety and Tolerability Analysis of Melflufen plus Dexamethasone in Patients with Relapsed/Refractory MM
12/01/2021
Melfulen plus dexamethasone shows consistent safety and tolerability when compared to pomalidomide and dexamethasone.
Melfulen plus dexamethasone shows consistent safety and tolerability when compared to pomalidomide and dexamethasone.
Melfulen plus dexamethasone...
12/01/2021
Oncology
Conference Insider
Combination Daratumumab and Dexamethasone Shows Promising Efficacy in Patients with RRMM and Severe Renal Impairment
12/01/2021
Daratumumab, in combination with dexamethasone, demonstrated promising efficacy with manageable safety in patients with RRMM and severe renal impairment or on dialysis.
Daratumumab, in combination with dexamethasone, demonstrated promising efficacy with manageable safety in patients with RRMM and severe renal impairment or on dialysis.
Daratumumab, in combination with...
12/01/2021
Oncology
mm
Conference Coverage
Ixazomib and Daratumumab Demonstrate Tolerable Safety for Elderly Patients with Relapsed/Refractory MM
12/01/2021
When given to elderly and frail patients with relapsed/refractory MM, combination ixazomib and daratumumab, without dexamethasone, showed favorable safety.
When given to elderly and frail patients with relapsed/refractory MM, combination ixazomib and daratumumab, without dexamethasone, showed favorable safety.
When given to elderly and frail...
12/01/2021
Oncology
mm
Conference Coverage
Ruxolitinib with Steroids Shows Promise in Patients with Relapsed/Refractory MM
11/30/2021
Ruxolitinib in combination with steroids is a promising treatment option for heavily pretreated patients with relapsed/refractory MM.
Ruxolitinib in combination with steroids is a promising treatment option for heavily pretreated patients with relapsed/refractory MM.
Ruxolitinib in combination with...
11/30/2021
Oncology
mm
Conference Coverage
Venetoclax Plus Daratumumab and Dexamethasone Yields Tolerable Safety in Patients with Relapsed/Refractory MM
11/29/2021
Preliminary results from a phase 1/2 trial showed that venetoclax plus daratumumab and dexamethasone demonstrates a tolerable safety profile in patients with relapsed/refractory MM.
Preliminary results from a phase 1/2 trial showed that venetoclax plus daratumumab and dexamethasone demonstrates a tolerable safety profile in patients with relapsed/refractory MM.
Preliminary results from a phase...
11/29/2021
Oncology
Conference Coverage
Adding Venetoclax to Bortezomib and Dexamethasone Improves PFS in Patients with Relapsed/Refractory MM
11/28/2021
Results from the BELLINI trial showed adding venetoclax to bortezomib and dexamethasone showed improved PFS but increased mortality in patients with relapsed/refractory MM.
Results from the BELLINI trial showed adding venetoclax to bortezomib and dexamethasone showed improved PFS but increased mortality in patients with relapsed/refractory MM.
Results from the BELLINI trial...
11/28/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 18 ⁠–⁠ September 20
September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use